Comparison of Intravitreal Afl ibercept and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion


Retina-Vitreus, vol.27, no.4, pp.323-327, 2018 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 4
  • Publication Date: 2018
  • Journal Name: Retina-Vitreus
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.323-327
  • Istanbul Medipol University Affiliated: Yes


Purpose: To compare the effi cacy of intravitreal injection of ranibizumab and afl ibercept on the treatment of macular edema due to branchretinal vein occlusion (BRVO).Materials and Methods: In this retrospective study; eyes with macular edema secondary to BRVO which treated with intravitreal ranibi-zumab (IVR) or afl ibercept( IVA) and followed at least 12 months between September 2012 and March 2016 were reviewed. Mean numberof injections and changes in two groups’ best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured by opticalcoherence tomography at month 1, 3, 6 and 12 were reviewed and compared.Results: Mean BCVA improved signifi cantly in IVR group (p=0.03, 0.04, 0.02 and 0.03 respectively) and IVA group (p=0.02, 0.04, 0.03and 0.03 respectively ; and CMT decreased signifi cantly in IVR group (p=0.02, 0.02, 0.02 and 0.03 respectively) and IVA group (p=0.001,0.03, 0.01 and 0.02 respectively) at 1, 3, 6 and 12th months. Mean number of injections per eye within twelve months were 3.4±1.2 in rani-bizumab group, and 2.2±1.1 in afl ibercept group (p=0.03). There were no signifi cant differences between two groups at month 12, includingfi nal BCVA, changes in BCVA, fi nal CMT, and changes in CMT (p> 0.05)Conclusion: Afl ibercept presented similar decrease in CMT and improvement in BCVA with lesser number of injections for macular edemadue to BRVO.